Akums Drugs Acquires Oriflame India’s Manufacturing Business for ₹56 Crore

Akums Drugs and Pharmaceuticals Limited, through its subsidiary Pure and Cure Healthcare, has agreed to acquire the manufacturing business of Oriflame India Private Limited for an all-cash consideration of ₹56 crore. The transaction was finalized on July 23, 2026, with completion expected by August 31, 2026. Key Deal Highlights: Assets Acquired: Two manufacturing plants (Roorkee, Uttarakhand and Noida, Uttar Pradesh) and a leased warehouse facility in Noida. Strategic Rationale: This move marks Akums’ strategic entry into the color cosmetics market, significantly expanding its existing footprint in the skincare and wellness segments while instantly boosting its manufacturing capacity. Key Exclusion: The deal is strictly for the manufacturing assets; it does not include the trademark or marketing rights for Oriflame’s products in India. Strategic Outlook: This acquisition allows Akums to rapidly capitalize on the high-growth Indian cosmetics and personal care market. By securing established, ready-to-use manufacturing infrastructure, the company can accelerate its contract manufacturing (CDMO) offerings, diversify its revenue streams beyond traditional pharmaceuticals, and strengthen its position as a comprehensive health and wellness manufacturing partner. $AKUMS